Beverly Hills, CA, 21 July 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced the appointment of Lynne Rollins as its new Chief Financial Officer (CFO). The appointment is effective immediately.
Lynne brings over 35 years’ of experience in the healthcare industry across finance, strategic planning and business development. Following senior positions at Baxter Healthcare Corporation, Lynne has advised over 30 startup medical device and biopharmaceutical companies including HighLife Medical, Syndax Pharmaceuticals and Calixa Therapeutics. Lynne has a B.S. in Finance from California State University and a MBA from Pepperdine University.